

ASX & MEDIA RELEASE**Notification to ineligible shareholders****Not for release or distribution in the United States****2 September 2019**

Attached is a sample of the letter that will be provided to shareholders who are ineligible to participate in the 1 for 5.91 pro-rata accelerated non-renounceable entitlement offer of new IDX shares, which was announced on Monday, 26 August 2019.

For further details contact**Integral Diagnostics**

Dr Ian Kadish, Managing Director & CEO

M: 0400 018 034

Integral Diagnostics

Anne Lockwood, CFO

M: 0410 632 640

About IDX:

Integral Diagnostics (IDX) is a leading provider of medical imaging services across Australia and New Zealand. The company provides state of the art diagnostic services to patients and their referrers at 53 radiology clinics, including 13 hospital sites. IDX employs some of Australasia's leading radiologists and nuclear medicine specialists in a unique medical leadership model that ensures quality patient care, service and access. Good medicine is good business.

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

2 September 2019

Dear Shareholder,

**ACCELERATED PRO-RATA NON-RENOUCEABLE ENTITLEMENT OFFER –
NOTIFICATION TO INELIGIBLE RETAIL SHAREHOLDERS**

On Monday, 26 August 2019, Integral Diagnostics Limited (**IDX**) announced that it was conducting an accelerated pro-rata accelerated non-renounceable entitlement offer (**Entitlement Offer**) of approximately \$72 million in new ordinary shares in IDX (**New Shares**) on a 1 for 5.91 basis to eligible shareholders, at an offer price of \$2.71 per New Share (**Offer Price**). The proceeds of the Entitlement Offer will be used to partially fund the acquisition of Imaging Queensland and pay associated transaction costs.

The Entitlement Offer is being made without a prospectus or product disclosure document in accordance with section 708AA of the Corporations Act 2001 (Cth) (**Corporations Act**) as modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84. The Entitlement Offer comprises an institutional entitlement offer (**Institutional Entitlement Offer**) and an offer to Eligible Retail Shareholders (as defined below) to participate on the same terms (**Retail Entitlement Offer**). The Institutional Entitlement Offer has already closed and the results announced to ASX.

The Entitlement Offer is lead managed and fully underwritten by Macquarie Capital (Australia) Limited (**Lead Manager** or **Underwriter**).

An offer booklet in relation to the Retail Entitlement Offer will be lodged with the ASX and mailed to Eligible Retail Shareholders on or around Monday, 2 September 2019.

This is a letter to inform you that you are not an Eligible Retail Shareholder for the purposes of the Retail Entitlement Offer. This letter is not an offer to issue New Shares to you, nor an invitation to apply for New Shares. **You are not required to do anything in response to this letter but there may be financial implications for you as a result of the Entitlement Offer that you should be aware of.**

Eligibility Criteria

Shareholders who are eligible to participate in the Retail Entitlement Offer (**Eligible Retail Shareholders**) are those persons who:

- (a) are registered as a holder of fully paid ordinary shares in IDX as at 7.00pm (Sydney time) on Wednesday, 28 August 2019;
- (b) have a registered address on IDX' share register that is in Australia or New Zealand or are a shareholder that IDX has otherwise determined is eligible to participate;
- (c) are not in the United States and are not acting for the account or benefit of a person in the United States with respect to their shares in IDX (to the extent such person holds IDX shares for the account or benefit of such person in the United States);

- (d) were not invited to participate (other than as nominee, in respect of the other underlying holdings) in the Institutional Entitlement Offer (and were not otherwise treated as an ineligible institutional shareholder under the Institutional Entitlement Offer); and
- (e) are eligible under all applicable securities laws to receive an offer under the Retail Entitlement Offer.

IDX has determined, pursuant to section 9A of the Corporations Act and ASX Listing Rule 7.7.1(a), that it would be unreasonable to make offers to shareholders in all countries outside Australia or New Zealand in connection with the Retail Entitlement Offer. This is due to the legal and regulatory requirements in countries other than Australia or New Zealand and the potential costs to IDX of complying with these requirements, compared with the relatively small number of shareholders in those countries, the relatively small number of existing IDX ordinary shares they hold and the relatively low value of New Shares to which those shareholders would otherwise be entitled to subscribe for.

Determination of eligibility of investors for the purposes of the Retail Entitlement Offer is determined by IDX with reference to a number of matters. The Underwriter and each of its affiliates and related bodies corporate and each of their respective directors, officers, partners, employees, advisers and agents disclaim any liability in respect of any determination as to eligibility, to the maximum extent permitted by law.

Unfortunately, according to our records, you do not satisfy the eligibility criteria for an Eligible Retail Shareholder as stated above. Accordingly, in compliance with ASX Listing Rule 7.7.1(b) and section 9A(3) of the Corporations Act, IDX wishes to advise you that it will not be extending the Retail Entitlement Offer to you and you will not be able to subscribe for New Shares under the Retail Entitlement Offer. You will not be sent the documents relating to the Retail Entitlement Offer or be able to subscribe for New Shares under the Retail Entitlement Offer.

Notwithstanding the above, IDX may agree to extend the Retail Entitlement Offer to certain institutional shareholders in foreign jurisdictions who did not participate in the Institutional Entitlement Offer subject to compliance with applicable laws.

As the Retail Entitlement Offer is non-renounceable, you will not receive any payment or value for entitlements in respect of any New Shares that would have been offered to you if you were eligible.

If you have any questions in relation to any of the above matters, please contact the IDX Shareholder Information Line on 1300 850 505 (within Australia) or +61 3 9415 4000 (outside Australia) from 8.30am to 5.00pm (Sydney time), Monday to Friday. For other questions, you should consult your broker, solicitor, accountant, financial adviser or other professional adviser.

On behalf of IDX, we regret that you are not eligible to participate in the Entitlement Offer and thank you for your continued support.



T | +61 3 5339 0704
E | info@integraldiagnostics.com.au

Level 8, 14-20 Blackwood St
North Melbourne Vic 3051

www.integraldiagnostics.com.au

Yours sincerely,

Kirsty Lally
Company Secretary
Integral Diagnostics Limited